Simplify and intensify upstream bioprocessing. XCell ATF® intensification solves manufacturing capacity, productivity, and throughput challenges.
NEW | Xcell™ Lab System
The XCell™ Lab system is designed and engineered as a complete solution. The XCell™ Lab system integrates.. NEED INTRO
- Engineering-designed controller promotes increased intensification
- Configurable set-up delivers high throughput - a single manifold supports up to 8 XCell ATF® devices
- Software enables precise technical control with a user-friendly interface
- New XCell ATF® 1 Device for low volume intensification ready for scale-up
- Repligen global technical support ensures successful implementation and scale-up
XCell™ Lab System
Fast and easy intensification that scales to manufacturing
DELIVER MORE,
FASTER
Increase throughput:
more programs,
more molecules
Increase productivity:
more product per batch
Increase capacity:
more batches per facility
TRANSFORM YOUR BUSINESS DECISIONS
Reduce bioreactor size,
especially < 2000L
Save > $250 million by solving facility-fit challenges
Alternative to facility expansion
- Lower cost
- Lower risk
- Faster results
XCELL™ LAB
CONTROLLER
Design simplicity:
software, hardware, device
Precision pumping enables robust development
More process data for improved characterization
Reduced media cost
How and why XCell ATF® Technology works
The XCell ATF® System is based on award-winning alternating tangential flow (ATF) technology, created by the action of a diaphragm moving upward and downward within a pump head, connected to a filter housing and attached to a bioreactor. Alternating tangential flow is attained by the action of a diaphragm pump.
XCell ATF® Devices
100% cell retention, 80% faster implementation, no autoclave
100% cell retention, high cell densities and product yields
The XCell ATF® Devices come in multiple sizes from lab-scale to production-scale. Each device consists of a proprietary diaphragm pump and a single-use hollow fiber filter module, for use with an XCell™ Controller.
Repligen develops and manufactures products for the biopharmaceutical industry under an ISO 9001 quality management system. We focus on the timely delivery of high quality, consistent and robust products, to ensure business continuity for our customers.
XCell ATF® intensification from Process development to manufacturing
XCell ATF® applications
UNDER CONSTRUCTION
Perfusion, or upstream continuous processing, has been used since the 1980s. High cell density perfusion with XCell ATF® devices delivers higher cell concentration and cell viability.
N-1 perfusion refers to the intensification of cell growth in the N-1 bioreactor prior to the production N bioreactor, whh remains in fed-batch mode. This process enables high cell density seeding of the production bioreactor.
Fed-Batch:
High Productivity Harvest
High Productivity Harvest (HPH) is a novel application developed by Repligen that enables you to harvest a fed-batch bioreactor in a fully sterile manner while eliminating both centrifugation and depth filtration.
REPLIGEN technical support ENSUres Success
The Repligen Field Application team with expertise in XCell ATF® technology will provide support from consultation to implementation globally.
Consultation |
Evaluation |
Development |
Implementation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Resources
High Productivity Harvest: A Novel Approach to Fed-batch Process Intensification
Mitigation of Protein Retention in Perfusion Process and Effect of Filter Pore Size
Demonstration of XCell ATF® 2 and XCell ATF® 6 Single-use Performance
Mitigation of Protein Retention in High Density Perfusion Process
Tools for Intensification of Cell Culture Production and Continuous Downstream Processing
ATF Perfusion Technology: Improved Fed-Batch Throughput and Reduced Seed Train Expansion
Special Report on Continuous Bioprocessing: Upstream, Downstream, Ready for Prime Time?
WuXi Biologics Expands Perfusion Cell Culture Capabilities using ATF 10 System
Continuous Manufacturing: A Changing Processing Paradigm
Developing an upstream process for a monoclonal antibody including medium optimization
Frequently asked questions | perfusion